Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

At week 72, the mean percent change in weight was −20.2% (95% CI, −21.4 to −19.1) with tirzepatide and −13.7% (95% CI, −14.9 to −12.6) with semaglutide (P < .001), while waist ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period for the efficacy estimand i. These findings were published in The New England ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

CHICAGO — In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according to new data from the SURMOUNT-1 study. As Healio previously ...

Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these ... hormone therapy enhances the effectiveness of tirzepatide for weight loss in ...

"Tirzepatide: The weight-loss drug that also shrinks breast tumors in mice." ScienceDaily. ScienceDaily, 13 July 2025. <www.sciencedaily.com / releases / 2025 / 07 / 250713031436.htm>.

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models ...

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatmentCombination of oral PL7737 and tirzepatide resulted in ...